According to Reuters, for every possible drug, Schrödinger routinely evaluates thousands of molecules, basing his tests on physics, but he will now be able to do this task with the help of Machine Learning systems.
Through collaboration, the entire pharmaceutical industry (comprising more than 3,000 companies, from start-ups to multinationals) will be able to further accelerate the discovery of drugs on a supercomputing scale.
“The discovery of computational drugs is improving accuracy with Schrödinger’s advanced combination of simulation and machine learning,” said Kimberly Powell, vice president of Nvidia Health Care.
Not just AI, but Data Centers
In addition to this partnership, Nvidia’s focus on new business development is on the rise, as it also introduced a new chipset: Grace.
Intel is the world’s largest manufacturer of CPUs for data center servers, but has seen increasing competition from Arm-based chips. With its “Grace” server processor, Nvidia will be the largest chip company to date by challenging Intel in its key market.
Shares of Nvidia rose 2.6% and those of Intel fell 4% in noon operations after the news.
Arm technology is driving chips on most smartphones, but in recent years it has made its way into data centers, with companies like Amazon and Ampere Computing designing chips for those companies.
Nvidia’s entry into the market could accelerate Arm raids on data centers. Nvidia chips have traditionally been used as “accelerators” along with existing CPUs from Intel, AMD, or others, unloading some of the computer work from them and speeding up the computer system in general.
By manufacturing its own CPU, Nvidia faces Intel and AMD directly for the first time. In the opening speech of the GTC, Nvidia CEO Jensen Huang described the new server chip as the “final piece of the puzzle” that will unite Nvidia’s graphics and network chips to form the “basic modern data center building block”.